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Around 70 % of ovarian cancer patients relapse after primary cytoreductive surgery and standard first-line chemo-
therapy. The biology of relapse remains unclear, but cancer stem cells seem to play an important role. There are still 
some areas of controversy on how to manage these relapses and or progressions that occur almost unavoidably in 
the course of this disease with shorter intervals between them as the natural history of this disease develops. The goal 
of treatments investigated in this neoplasm has shifted to maintenance therapy, trying to extend the progression free 
intervals in a disease that is becoming more and more protracted.
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Background
Ovarian cancer (OC) is the second most lethal gyneco-
logical neoplasia and the seventh cause of cancer-related 
mortality in women around the world (Globocan 2012). 
Nearly 70 % of the patients are diagnosed with advanced-
stage due to the failure of screening methods for detect-
ing early-stage disease (Partridge et  al. 2009; Bast et  al. 
2007; Gohagan et  al. 2000; Chudecka-Głaz 2015). Thus, 
most patients will relapse within the first 2  years after 
diagnosis, even after an optimal primary cytoreductive 
surgery and six cycles of the standard adjuvant chemo-
therapy with carboplatin/paclitaxel (Fig. 1) (International 
Collaborative Ovarian Neoplasm Group 2002).
Although several regimes have been evaluated to 
improve outcomes (Armstrong et  al. 2006; Katsumata 
et  al. 2013; Bookman et  al. 2009; du Bois et  al. 2014; 
Burger et al. 2011; Oza et al. 2015b), relapse seems una-
voidable. The main objective of this review is to evalu-
ate management of relapse and maintenance therapies 
in phase II/III trials. Therefore, I carried out a review 
based on the full-text published articles using key words 
“relapsed ovarian cancer” and “recurrent ovarian cancer” 
in all major medical article searchers.
Biology of relapse
Metastases or relapses seem to be generated by “cancer 
stem cells” (CSCs) (Green 1989), a sub-population of 
cells, chemo and radio-resistant by expression of chemo 
resistant makers like aldehyde-dehydrogenase 1, efflux-
drug transporters, or merely by staying quiescent in G0 
phase of the cell-cycle, until a “driver event” (paracrine/
endocrine factors) occurs and they proliferate to a more 
differentiated and chemo-sensitive population of cells 
(Charafe-Jauffret et  al. 2009; Shah and Landen 2014; 
Tomao et  al. 2014; Croker and Allan 2008; Zhang et  al. 
2014; O’Connor et al. 2014).
CSCs divide symmetrically (originate new CSCs) and 
asymmetrically (a daughter-cell starts to generate clones). 
So, CSCs originate relapse and guarantee their perpetuity 
and further relapses (Cojoc et al. 2015).
After chemotherapy (Ct) induced cytoreduction, the 
tumor microenvironment changes as it becomes less 
hypoxic. This “driver event” helps CSCs to prolifer-
ate, and its progeny does the same as they sense the 
new favorable conditions (Tomao et  al. 2014); neo-
vascularization(“angiogenic switch”) switches “on” and so 
this proliferating progeny becomes sensitive to chemo-
therapeutic drugs and PARPi; to repair DNA-damage 
that occurs during DNA-replication under hypoxia.
This is the biology underlying the maintenance phase 
after the cytoreduction achieved after second-line Ct 
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for relapse; clinically manifested in complete or partial 
response.
Management of relapse
There are several controversial issues (Walters Haygood 
et al. 2014):
Early versus delayed treatment, depending on the kind 
of “relapse”:
  • an increase CA 125 with no other evidence of dis-
ease.
  • or “clinical relapse”, evident through images (Ultra-
sound (US), Computed Tomography (CT) scan or 
PET/CT scan) or in physical examination.
MRC OVO5/EORTC 55955 included 1,442 patients, 
who after completion first line Ct were followed with CA 
125 every 3 months (Rustin et al. 2010). Those who dou-
bled baseline tumor marker in two consecutive measure-
ments (n = 592) were randomized to an “early treatment” 
arm (N = 265). In the “delayed treatment” arm (264), the 
treatment was initiated upon clinical relapse.
With a median follow-up of 56.9  months (m), there 
was no benefit for the “early treatment” arm in over-
all survival (OS) (HR 0.98, IC 95 % 0.80–1.20, p = 0.85). 
Median survival (in months) in “early” versus “delayed” 
treatment: 25.7 m (IC 95 % 23.0–27.9) versus 27.1 m (IC 
95 % 22.8–30.9).
The “early treatment” arm had a significantly shorter 
time to a second-line (4.8  m before (IC 95  % 3.6–5.3) 
and third-line of treatment. Quality of life (QoL) was 
deteriorated before (7.2 vs. 9.2  m with a good “Global 
health” score) and the time to deterioration was sig-
nificantly longer in the “delayed treatment” arm (3.2 vs. 
5.8 m, p = 0.002) (Rustin et al. 2010).
Therefore, CA 125 should be reconsidering in the 
follow-up of OC patients before starting and/or chang-
ing the treatment. Although it is useful for monitoring 
treatment efficacy, one should not modify the treatment, 
based only on this test.
Surgery of relapse. Secondary cytoreduction or second-
ary debulking is the surgery for resection of the site(s) 
of relapse to render the patient optimally debulked (R0) 
(Bristow et al. 2009).
Although most of the reports are retrospective series 
and subjected to “selection bias”, they report survival up 
to 35 m for patients who achieve an R0 after surgery of 
relapse (Bristow et  al. 2009; Harter et  al. 2006; Galaal 
et al. 2010; Wakabayashi et al. 2008). There is a score that 
predicts the chance of achieving an “optimal” secondary 
debulking (Harter et  al. 2006; Salani et  al. 2007). Glob-
ally, we can consider this intervention in “late” relapses 
(>12  m) or with a low volume of disease (Salani et  al. 
2007; Munkarah and Coleman 2004).
The results of AGO-DESKTOP (AGO Study Group 
2015) and NCI (2007), evaluating the benefits of this sur-
gery in relapses after 6 m of the last platinum-based Ct 
(platinum-sensitive relapse), are being awaited.
Second-line chemotherapy The combination is given for 
relapsed disease whether it is first, second or third line 
and depends mainly on the disease-free interval (DFI) 
(time between completion of first line Ct and clinical 
Fig. 1 Natural history of ovarian cancer evolution
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relapse; or progression-free interval (PFI) (time between 
the last Ct given for relapsed disease and progression).
According to these intervals, the relapse is:
Platinum‑refractory/resistant
Relapses during platinum treatment (refractory) or with 
a disease-free interval (DFI)/PFI <6  months (resistant). 
Usually symptomatic with large-volume disease, these 
relapses are frequent later in the course of this disease 
(shorter PFI). Once the treatment has been chosen, one 
should not only consider overall response rate (ORR) to 
achieve symptomatic palliation (pain, ascites, etc.), but 
QoL improvement.
Many trials have compared single agent versus combi-
nation Ct in this setting, with no difference in ORR nor 
in progression free survival (PFS) for the combinations, 
which result in increased toxicity (Sehouli et  al. 2008; 
Lortholary et  al. 2012) Pegylated liposomal doxorubicin 
(PLD) has demonstrated similar ORR with a more favora-
ble toxicity profile than with topotecan and gemcitabine 
(Gordon et al. 2004).
Although Ct combinations are not superior to single 
agent PLD, combination with bevacizumab (BEV) has 
improved the results (see “Bevacizumab”), and now is 
considered the best treatment in terms of ORR, PFS and 
QoL improvement in patients who had not received BEV 
previously (in combination with either weekly paclitaxel, 
PLD or topotecan).
Platinum‑sensitive
Relapses occurring >12 m of last platinum-based Ct, usu-
ally with low-volume disease, eventually candidate for 
secondary cytoreduction.
At least, three phase III, randomized trials show ben-
efit for platinum-combination Ct (plus PLD, gemcitabine 
or paclitaxel) versus platinum single-agent (Parmar et al. 
2003; Sandercock et al. 2002; Pfisterer et al. 2006).
Given its low toxicity profile (particularly in elderly 
patients) and no cumulative neurotoxicity, the preferred 
regimen is carboplatin/PLD (Wagner et  al. 2012; Kurtz 
et  al. 2011; Brundage et  al. 2012). Furthermore, BEV 
addition to platinum-based combinations (like carbopl-
atin/gemcitabine) improves ORR and PFS results (Poveda 
et al. 2011, 2014; Aghajanian et al. 2015).
Partially sensitive to platinum
Disease-free survival (DFS)/PFS between 6 and 
12  months from the last platinum-based Ct. Thus, arti-
ficially prolonging the platinum-free interval by incor-
porating a non-platinum regimen (trabectidin/PLD), 
saving platinum for a further relapse, has shown benefit 
in PFS and OS in the OVA 301 trial (Poveda et al. 2011). 
Although a similar proportion of patients in each arm 
of this trial received platinum-based Ct in subsequent 
relapse, the combination arm did so significantly later 
(Poveda et al. 2011).
INNOVATYON trial compares platinum-based com-
bination versus trabectidin/PLD (followed by plati-
num-based Ct for further relapse) in this setting (DFI 
6–12  months). The trial end points are DFS and OS. It 
has recently completed accrual and results are awaited 
(Poveda et al. 2014). Table 1 summarizes the Ct combi-
nations/singe agent according to “platinum-free-interval”.
Targeted agents plus second‑line chemotherapy
Anti-VEGF antibody (bevacizumab), VEGF dependent 
tirosine-kinase inhibitor (cediranib), and anti-angiopoie-
tin 1–2 pepto-antibody (trebananib) are targeted agents 
evaluated in clinical trials in association with chemother-
apy in different settings of relapsed disease.
Bevacizumab
Based on the results obtained by adding bevacizumab 
to first-line chemotherapy in GOG 218 and ICON 7 tri-
als (Burger et al. 2011; Oza et al. 2015b) (benefit in DFS), 
BEV was also evaluated in two phase III, randomized 
trials in the relapse setting: OCEANS (Aghajanian et al. 
2015) and AURELIA (Pujade-Lauraine et  al. 2014; Pov-
eda et al. 2015).
OCEANS randomized patients with platinum-sensi-
tive relapse to chemotherapy [carboplatin/gemcitabine 
(GC)] + placebo (PL) (GC + PL) versus the same regi-
men  +  bevacizumab (GC  +  BEV) concomitant with 
chemotherapy and as maintenance until disease pro-
gression. The GC +  BEV arm showed benefit in ORR 
(78.5 vs. 57.4 % p < 0.0001) and PFS (8.4 vs. 12.4 m (HR 
0.48, p < 0.0001); although no difference was observed 
in OS (GC +  BEV: 33.6  m; GC +  PL: 32.9  m; hazard 
ratio  =  0.95; log-rank p  =  0.65) (Aghajanian et  al. 
2015).
Table 1 Chemotherapy combinations/single agent accord-
ing to platinum-free-internal
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In the platinum-resistant setting, the AURELIA trial 
also randomized patients to a Ct  +  PL arm (investiga-
tor’s choice: weekly paclitaxel, PLD or topotecan) ver-
sus the same agents +  BEV, followed by a maintenance 
phase until disease progression. As shown in OCEANS, 
the combination with BEV arm was significantly superior 
in ORR (12.6 vs. 30.9 %, considering response by CA 125 
and RECIST) and PFS (3.4 vs. 6.7 m (HR0.48, p < 0.0001), 
albeit no difference in OS between the arms (HR 0.85 p 
NS) was observed. Although the study was not designed 
to detect differences between the three Ct + BEV com-
binations, the weekly paclitaxel (Pcl) +  BEV performed 
better in ORR (ORR CT + BEV: weekly Pcl 23.5 %, PLD: 
10.4 % and topotecan: 19.5 %) (Poveda et al. 2015).
Patients receiving BEV improved global OC QoL scores, 
and had a significant reduction in the number of paracen-
tesis needed to alleviate ascites (Stockler et al. 2014).
Table 2 compares the results of the four phase III trials 
evaluating BEV in OC either in first line setting or at relapse 
(GOG 218, ICON 7, OCEANS y AURELIA), as well as the 
sub-group analysis of the “high-risk” group in the ICON 7 
(Stage III R1 and IV) (Burger et al. 2011; Oza et al. 2015b; 
Pujade-Lauraine et al. 2014; Poveda et al. 2015; Ledermann 
et al. 2013; Raja et al. 2011; du Bois et al. 2016; European 
Medicine Agencies 2016; Matulonis et al. 2016; Marchetti 
et al. 2015; Lopez et al. 2013).
Given the higher HR in the trials (GOG 218, ICON 7, 
OCEANS and AURELIA trials) evaluating BEV in the 
relapse setting, we can infer that patients with large-
volume disease (platinum-resistant relapse) obtain the 
greatest reduction in risk of progression and a greater 
benefit in ORR and QoL.
FDA and EMA guidelines only approve BEV for 
relapsed patients who have not received this agent in the 
first line. Moreover, for platinum-sensitive relapse, the 
approval is only for “first” relapse.
Cediranib
It inhibits vascular endothelial growth factor (VEGF) 
receptor 1, 2 and 3 tyrosine kinases. ICON 6 was a phase 
III, randomized trial which evaluated the combination 
of cediranib (Ced) with platinum-based Ct, followed by 
maintenance therapy for platinum-sensitive relapsed 
(Monk et  al. 2015); patients were randomized (n =  465) 
to Ct + Ced (20 mg P.O daily) versus placebo. The experi-
mental arm showed a significant difference of 3.2 months 
in PFS and 2.7 m in OS (HR 0.68; log-rank test p = 0.0022). 
Most frequent adverse events were hypertension, diarrhea, 
hypothyroidism, dysphonia, bleeding, proteinuria, and 
fatigue (Raja et  al. 2011). Despite the benefit in PFS and 
OS, the submission for approval of this drug by FDA and 
EMA was withdrawn (Lord and Ashworth 2012).
Cediranib + olaparib (PARPi) combination has shown 
activity as a non-chemotherapy treatment for platinum-
sensitive relapsed OC (Lord and Ashworth 2012). It will 
be compared in a three-arm, phase III trial versus olapa-
rib versus standard platinum-based Ct in platinum-sensi-
tive relapse (Raja et al. 2011; Monk et al. 2015; Lord and 
Ashworth 2012).
Trebananib
It is a peptidic antibody (AMG 386) that blocks interac-
tion between angiopoietin receptors Ang 1 (promotes 
good quality neo vessels growth) and Ang 2 (related to 
the number of neo vessels), and their ligand Tie 2. Both 
receptors are over-expressed in OC.
Trebananib has shown activity as single agent in 
phase I trials and associated to weekly Pcl in phase II 
Table 2 Phase II/III trials with targeted agents in ovarian cancer (du Bois et al. 2014, 2016; Burger et al. 2011; Oza et al. 
2015a; Aghajanian et  al. 2015; Poveda et  al. 2015; Ledermann et  al. 2013; Matulonis et  al. 2016; European Medicine 
Agencies 2016; Marchetti et al. 2015)
* Difference in months
First line Relapse

























DFS/PFS* 3.8 1.7 5.6 0.7 4.0 3.1 4.0 1.8 3.3
DFS/PFS HR 0.72 0.81 0.77 0.84 0.48 0.57 0.35 BRCAm  
0.18
0.66 0.48
OS* 0.4 0.9 NA NR −1.8 2.7 2.0 1.7 3.3
OS HR 0.91 (NS) 0.99 (NS) (final) NR 1.03 (NS) 0.70 0.88 (NS) 0.86 (NS) 0.85 (NS) (final)
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trials, showing benefit in PFS + Ct (Lord and Ashworth 
2012).
TRINOVA 1 included 919 heavily pre-treated patients 
(≥3 lines) with relapsed OC and a platinum-free inter-
val ≤12  m (nearly 50  % of patients in each arm were 
“platinum- resistant”). They were randomized to treba-
nanib 15  mg/kg/week +  Pcl 80  mg/m2/week versus the 
same chemotherapy regimen + placebo. Median follow-
up: 18  m; primary end-point was PFS. The experimen-
tal arm had a significant advantage in PFS (HR 0.66 (IC 
95 % 0.57–0.77) p < 0.001). Although all patients showed 
improvement in this end-point, the sub-group with 
ascites benefited the most (HR 0.72 (IC 95 % 0.85–0.93) 
p  <  0.011). Trebananib arm also had better ORR and a 
longer time to subsequent treatment. Non-significant 
differences were observed in OS (HR 0.95 (IC 95  % 
0.81–1.11)).
Although the difference in Grade 3–4 serious adverse 
events was non-significant, the experimental arm showed 
a higher incidence of localized edema, pleural effusion, 
and ascites. This was the most frequent cause of treat-
ment discontinuation (20 % of the patients) (Monk et al. 
2015).
PARP inhibitors
These agents impair proper DNA repair by inhibiting 
PARP (Poly (ADP-ribose) polymerase) that has a key 
role in “base excision repair (BER), through which sin-
gle strand DNA damage is repaired. DNA poly adenosil 
ribosilation (PAR) is a key pathway where gathering all 
the machinery needed for reparation where single strand 
DNA is damaged (Marchetti et  al. 2015; Lord and Ash-
worth 2012; Li and Yu 2015; Mukhopadhyay et al. 2011, 
Chionh et al. 2011; Schreiber et al. 2006).
By inhibiting PARP, single strand DNA remains unre-
paired and the “replication fork” (DNA polymerase 
complex) is stalked, hence single strand breaks turn 
into a double strand-break. BRCA 1 & 2 proteins work 
as a scaffold for other factors important in “homologous 
recombination” (Hr), a high fidelity process to repair this 
type of DNA damage. Hr occurs only in G2 or M phases 
of the cell cycle because it requires the presence of the 
sister chromatid as a template to create an exact copy of 
the impaired DNA fragment.
Malfunction of these proteins—by germinal or somatic 
mutation or epigenetic inactivation of the genes (meth-
ylation)—creates a state of homologous-recombination 
efficiency (HRd), and the cell recurs to less efficient (low 
fidelity) mechanisms to repair DNA, like non-homol-
ogous end joining (NHEJ), through which the damaged 
fragment is excised and the 3′ and 5′ ends are joined. 
This implies cell loss of variable-length portions of DNA, 
which eventually leads to an extensive genomic loss and 
the cell incapability to survive (Marchetti et  al. 2015; 
Schreiber et al. 2006).
In HRd (like BRCA 1 & 2 mutated) cells, by inhibit-
ing PARP, we can create a “synthetic lethality” state: 
single-strand DNA damage cannot be repaired by BER 
and the cell is forced to use an inefficient mechanism to 
repair double-strand breaks, like NHEJ. This results in a 
large DNA loss. Without it, the cell losses critical genes 
for surviving and finally the cell dies (Audeh et al. 2010; 
Chen et  al. 2013; Cancer Genome Atlas Research Net-
work 2011; Liu et al. 2014b; Fong et al. 2010).
Around 20  % of OC patients have a germinal or 
somatic BRCA 1 or 2 mutated (BRCAm) plus 11 % with 
epigenetic inactivation of these genes (Oza et al. 2015a). 
Considering mutations in other genes involved in HR, up 
to 50 % of OC patients have a HRd, the so-called “BRCA-
ness syndrome”. This phenotype is more frequent (but 
not exclusive) in “platinum-sensitive relapse” OC. Thus, 
failure to repair the damage caused in DNA by plati-
num (inter/intra strand adducts that would normally be 
repaired by Hr or BER) is a surrogate of an HRd (Oza 
et al. 2015a; Ledermann et al. 2014).
Different PARP inhibitors (PARPi) have been or are 
under clinical investigation in different OC settings:
1. associated to first-line chemotherapy and as mainte-
nance (veliparib),
2. associated to second-line chemotherapy and as 
maintenance after platinum-sensitive relapse (olapa-
rib, rucaparib, niraparib)
3. as single agent in heavily pre-treated patients (olapa-
rib) (Cancer Genome Atlas Research Network 2011).
Trials with PARPi
These trials evaluate PARPi (olaparib) associated with 
second-line Ct and, as maintenance treatment or as 
maintenance only.
An open label phase II trial randomized 162 platinum-
sensitive relapsed OC patients to platinum-based Ct 
(carboplatin-paclitaxel) + olaparib 200 mg P.O BID (days 
1–10) concurrent with chemotherapy (81 patients) or 
chemotherapy alone (75 patients); 121 patients continued 
receiving olaparib as maintenance (400 mg P.O, BID, until 
progression) or placebo (66 in the olaparib + chemother-
apy arm and 55 in the chemotherapy alone arm) (Gourley 
et al. 2014).
BRCA mutation status was known in 107 patients: 41 
(38  %) had BRCA mutated (20 in the experimental arm 
and 21 in the Ct alone arm). PFS was significantly longer 
in the olaparib + Ct arm (median 12.2 m [95 % CI 9.7–
15.0]) than in the Ct alone arm (median 9.6 m [95 % CI 
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9.1–9.7) (HR 0.51 [95 % CI 0.34–0.77]; p = 0.0012), par-
ticularly in BRCAmut (HR 0.21 [0.08–0.55]; p = 0.0015). In 
the concurrent phase, the most frequent adverse events 
with a difference of at least 10 % between the arms were 
alopecia (60 [74 %] out of 81 vs. 44 [59 %] out of 75), nau-
sea (56 [69 %] vs. 43 [57 %]), neutropenia (40 [49 %] vs. 29 
[39 %]), diarrhea (34 [42 %] vs. 20 [27 %]), headache (27 
[33 %] vs. 7 [9 %]), peripheral neuropathy (25 [31 %] vs. 
14 [19 %]), and dyspepsia (21 [26 %] vs. 9 [12 %]); most of 
them were mild to moderate. Grade ≥3 events were neu-
tropenia (in 35 [43 %] out of 81 patients in the experimen-
tal arm vs. 26 [35 %] out of 75, and anemia (7 [9 %] vs. 5 
[7 %]). Serious adverse events were reported in 12 (15 %) 
out of 81 patient in the olaparib + Ct arm and in 16 out of 
75 (21 %) in the standard arm (Gourley et al. 2014).
Although it was not designed to evaluate the benefit of 
adding olaparib to Ct or as maintenance only; lack of dif-
ference between the arms in ORR and the split of the PFS 
curves at the beginning of the maintenance phase suggest 
that the benefit of adding PARPi occurs in this period. 
Toxicities were more conspicuous in the concurrent 
phase, and affected tissues, where the impact of incorpo-
rating an agent affecting DNA repair would be greater: 
bone marrow and gastro-intestinal mucosae.
Maintenance treatment after relapse
This treatment is given after partial or complete response 
after second-line Ct (±secondary cytoreductive surgery) 
for relapsed OC until progression; thus it should be:
  • effective to achieve a longer time to progression 
(PFS)
  • tolerable as a long-lasting treatment (i.e. ≥2  years), 
without impairing QoL.
The same principles apply to the biological mechanisms 
underlying of this maintenance phase. So, the targetable 
events are angiogenesis and DNA replication/repair.
Maintenance with anti‑angiogenic agents
Bevacizumab
OCEANS (Aghajanian et  al. 2015) and AURELIA 
(Pujade-Lauraine et  al. 2014) evaluated BEV as mainte-
nance either after platinum-sensitive or platinum-resist-
ant relapse. Adding bevacizumab to OC treatment seems 
to be directly proportional to the volume of disease, given 
that the greatest benefit in reducing the risk of progres-
sion was seen in patients with the greatest volume of dis-
ease at relapse (platinum-resistant), who also obtained a 
greater advantage in ORR and in QoL (Pujade-Lauraine 
et al. 2014; Poveda et al. 2015).
In both trials, BEV was well tolerated, had low-dis-
continuation rates and less than 5  % Gr 3–4 adverse 
events, mostly hypertension, arterial/venous thrombo-
embolic events or fistulae. At progression, roughly 30 % 
of patients in the placebo arm received an anti-angio-
genic agent, which may explain the lack of OS difference 
between the arms.
At relapse, bevacizumab has only been approved for 
patients who had not received it in first line.
Cediranib
See “Cediranib” in “Targeted agents plus second-line 
chemotherapy” section.
Maintenance with PARPi
Olaparib was evaluated as maintenance treatment after 
platinum-sensitive relapse in “Study 19” (Matulonis et al. 
2016). It included 265 patients regardless their BRCA sta-
tus who after achieving complete or partial response to 
induction platinum-based Ct were randomized to olapa-
rib 400 mg P.O, BID, until 1progression or PL.
Olaparib arm showed a significantly longer PFS (8.4 
vs. 4.8 m (HR 0.35 [95 % CI 0.25–0.49] p < 0.001), time 
to first subsequent treatment and time to subsequent 
relapse. However, there were no differences in OS: HR 
0.94 [95 % CI 0.63–1.39] p = 0.75. It was generally well 
tolerated. The most common toxicities were hematologi-
cal (anemia and leucopenia), gastro-intestinal (nausea, 
vomiting, and abdominal pain), and others like asthe-
nia and fatigue. Most of the toxicities were Grade 1–2 
and could be managed with dose reduction. The risk of 
myelodysplastic syndrome and acute leukemia was <3 %. 
By January 2014, 19 patients in the olaparib arm contin-
ued under treatment, 24 (18 %) out of 136 patients in the 
experimental arm had received olaparib for more than 
3 years.
When the study began, BRCA status was known only 
for 30 % of patients, but a subsequent analysis was per-
formed to evaluate the differential benefit of BRCAm 
patients. As expected BRCA 1 & 2m patients (56 % in the 
olaparib arm vs. 50 % in the PL arm) had a greater benefit 
in all end-points: median PFS of 11.2  m ([95  % CI 8.3–
no calculable] vs. 4.3  m [3.0–5.4]; HR 0.18 [0.10–0.31]; 
p < 0.0001).
This is the greatest benefit obtained by any agent in 
terms of PFS in OC. However, BRCAwt patients also ben-
efited from olaparib maintenance, although the differ-
ence was less (7.4  m [5.5–10.3] vs. 5.5  m [3.7–5.6]; HR 
0.54 [0.34–0.85]; p =  0.0075) (Fig.  2). Since up to 50  % 
of platinum-sensitive relapsed patients have HRd, this 
would make them sensitive to this PARPi. Nevertheless, 
based on the greater benefit observed in BRCAmut (ger-
minal or somatic), EMA approved olaparib as mainte-
nance therapy after response to platinum-based Ct in this 
population at ≥1st platinum-sensitive relapse.
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Grade ≥3 toxicities in the olaparib arm were fatigue 
(in 10 [7 %] patients vs. 4 [3 %] in the placebo arm) and 
anemia (7 [5 %] vs. 1 [<1 %]). Serious adverse events were 
reported in 25 patients (18  %) in the experimental arm 
and 11 (9 %) in the PL. There were no differences in toler-
ability between BRCAmut and BRCAwt population (Mar-
chetti et al. 2015).
In a second interim analysis (with 38 % of maturity) OS 
was not significantly different between the two groups 
(HR 0.88 [95 % CI 0.64–1.21]; p = 0.44); the same applies 
to BRCAmut patients (HR 0.73 [0.45–1.17]; p = 0.19) and 
BRCAwt (HR 0.99 [0.63–1.55]; p = 0.96).
Predictive factors in OC
Although adding targeted agents to Ct or as maintenance 
has improved the results obtained with Ct alone (longer 
PFS and higher ORR), it is necessary to identify “predic-
tive factors” to distinguish which subgroup of patients 
benefit the most.
Bevacizumab
ICON 7 (n = 284 total, 18.6 % patients analyzed) evalu-
ated if the differentiated, immuno-reactive, mesenchy-
mal, and proliferative genomic profiles described in OC65 
derived differential benefit from BEV (Gourley et  al. 
2014; McNeish et al. 2015).
The mesenchymal and proliferative sub-types were 
benefited by adding BEV to first-line Ct and the 
immuno-reactive did not (Birrer et  al. 2015). A valida-
tion analysis in a prospective larger group of patients is 
required to confirm these data, as well as to assess if this 
differential benefit is applicable to relapsed patients.
At ASCO 2015, data were presented showing the level 
of expression of CD 31 as a predictive factor for BEV (Liu 
et al. 2014a).
PARPi
As seen before, BRCA mutational status is not only a 
predictive factor for response to Ct (Alsop et  al. 2012) 
(platinum combinations, tarbectidin/PLD, PLD), but 
also identifies patients who benefit the most with olapa-
rib maintenance therapy (Alsop et al. 2012). Since up to 
30 % of BRCAmut do not have family history of cancer and 
25  % are older than 65  years old (SGO 2014), the Soci-
ety of Gynecological Oncology recommends to test all 
patients with OC at diagnosis and to perform a complete 
mutational analysis of these genes through NGS (next 
generation sequence).
BRCA 1 & 2 are not the only genes responsible for a HRd. 
So, different panels of genes are being tested spanning 
between 5 and 25 genes involved in Hr, trying to enlarge 
the spectrum of patients potentially sensitive to PARPi.
ARIEL 2 validated a biomarker assay which could pre-
dict benefit with rucaparib as maintenance therapy after 
platinum-sensitive relapse (McNeish et al. 2015; Liu et al. 
2014a). Through whole genomic sequencing from the 
BRCAm (n=136) BRCAwt (n=118)
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Fig. 2 “Study 19”, progression free survival according to BRCA status. Adapted from Matulonis et al. (2016), Ledermann et al. (2014), Birrer et al. 
(2015)
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tumor, a genomic signature called “LOH (loss of hetero-
cigozity) signature” was identified, which is the expres-
sion of the large un-replicated areas of DNA, shown in 
the genomic sequencing as “DNA scars”. Patients with 
this “LOH signature” (“biomarker positive”, similar to the 
one BRCAm patients had), benefited the most with this 
PARPi not only in ORR, but also in PFS in comparison 
with the ones not expressing this signature (“biomarker 
negative”), and behave like BRCAm patients (n = 25) [HR 
0.61(IC 95 % 0.41–0.92)] (Alsop et al. 2012).


















































































Fig. 3 Ceridanib + olaparib versus olaparib in platinum sensitive relapse (PFS according to BRCA status). Adapted from Liu et al. (2014a)
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Non‑chemotherapy combinations at relapse
Olaparib (Olap) and anti-angiogenic Ced combination 
was compared against Olap single agent in platinum-
sensitive relapsed ovarian cancer. Ninety patients were 
randomized to Olap 400 mg BID P.O (46 patients) or the 
combination of Ced/Olap (Olap 200 mg BID; Ced 30 mg 
P.O daily) (44 patients). The combination arm showed 
benefit in ORR and PFS especially in BRCAwt patients; 48 
patients were BRCAmut (25 Olap; 23 Ced/Olap). Median 
PFS was 9.0 m in the Olap arm and 17.7 m for Ced/Olap 
(HR 2.9, 95 % CI 1.5–5.6, p = 0.001). For ORR: Olap 56 % 
and 84 % for the combination (p = 0.008). Gr 3/4 toxici-
ties were 70 % in the Ced/Olap arm and 7 % for Olap. The 
most frequent were fatigue (27 % Ced/Olap vs. 7 % Olap), 
diarrhea (23 vs. 0 %), and hypertension (39 vs. 0 %).
The differential benefit for BRCAwt patients may be 
explained by the generation of oxygen reactive species by 
Ced, which damage DNA pushing the cell to use a repair-
ing system inhibited by the PARPi (Liu et al. 2014b; SGO 
2014; Goss et al. 2009; NCI 2015) (Fig. 3).
This combination is being tested against chemotherapy 
in platinum-sensitive relapsed OC (du Bois et al. 2014).
Conclusions
Management of relapsed OC involves many decisions; 
thus, there is still no firm clinical evidence: (1) early 
(based only on a raising CA 125) versus delayed treat-
ment of relapse; (2) to perform or not secondary cytore-
ductive surgery; (3) what chemotherapy combination 
should be used (platinum vs. non-platinum); (4) anti-
angiogenic agents in the first line versus at relapse, and 
(5) how to select the population who may benefit with 
PARPi maintenance therapy.
A deeper knowledge of the biology of the maintenance 
phase, as well as the molecular and cellular events (where 
cancer stem cells would play an important role in relapse/
progression) may lead to targeted therapeutic strategies 
which would replace chemotherapy combinations for 
non-chemotherapy regimens, based on patient’s specific 
predictive factors.
So far, BRCA mutational status is the only predic-
tive factor in OC, and the benefit obtained with PARPi 
(Olap) in BRCAm has been the greatest among the differ-
ent agents used in this disease. The reason is that for the 
first time in OC, a treatment is used based on a predic-
tive factor.
The challenge is to identify other genes or a genomic 
signature that could enrich the population who may ben-
efit from these agents, as well as other predictive factors 
for antiangiogenic agents.
This may allow tailoring specific therapies to obtain the 
greatest benefit with low-toxicity profile in a disease in 
which maintenance therapies delay progression/relapse.
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